BridgeBio Pharma, Inc.

NasdaqGS:BBIO Stock Report

Market Cap: US$13.0b

BridgeBio Pharma Valuation

Is BBIO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BBIO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: BBIO ($66.61) is trading below our estimate of future cash flow value ($283.06)

Significantly Below Future Cash Flow Value: BBIO is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BBIO?

Key metric: As BBIO is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for BBIO. This is calculated by dividing BBIO's market cap by their current revenue.
What is BBIO's PS Ratio?
PS Ratio18.3x
SalesUS$713.07m
Market CapUS$13.02b

Price to Sales Ratio vs Peers

How does BBIO's PS Ratio compare to its peers?

The above table shows the PS ratio for BBIO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average14.8x
KRYS Krystal Biotech
22.6x34.70%US$10.0b
ARWR Arrowhead Pharmaceuticals
14x29.05%US$9.4b
ASND Ascendis Pharma
12.9x24.03%US$15.5b
MDGL Madrigal Pharmaceuticals
9.6x27.97%US$12.3b
BBIO BridgeBio Pharma
18.3x36.18%US$13.0b

Price-To-Sales vs Peers: BBIO is expensive based on its Price-To-Sales Ratio (18.3x) compared to the peer average (14.8x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does BBIO's PS Ratio compare vs other companies in the US Biotechs Industry?

124 CompaniesPrice / SalesEstimated GrowthMarket Cap
BIIB Biogen
3.2x2.60%US$31.84b
BMRN BioMarin Pharmaceutical
3.6x10.36%US$12.38b
LEGN Legend Biotech
2.7x15.48%US$3.41b
BCRX BioCryst Pharmaceuticals
2.4x7.14%US$2.22b
BBIO 18.3xIndustry Avg. 12.5xNo. of Companies124PS01632486480+
124 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: BBIO is expensive based on its Price-To-Sales Ratio (18.3x) compared to the US Biotechs industry average (12.5x).

Price to Sales Ratio vs Fair Ratio

What is BBIO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BBIO PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio18.3x
Fair PS Ratio19.5x

Price-To-Sales vs Fair Ratio: BBIO is good value based on its Price-To-Sales Ratio (18.3x) compared to the estimated Fair Price-To-Sales Ratio (19.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BBIO forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$66.61
US$109.10
+63.78%
14.17%US$157.00US$80.00n/a21
Sep ’27US$76.57
US$109.10
+42.48%
14.17%US$157.00US$80.00n/a21
Aug ’27US$80.09
US$105.26
+31.42%
15.55%US$157.00US$80.00n/a21
Jul ’27US$74.52
US$102.28
+37.25%
16.45%US$157.00US$76.00n/a23
Jun ’27US$65.36
US$102.65
+57.06%
16.72%US$157.00US$76.00n/a22
May ’27US$68.56
US$101.19
+47.59%
15.30%US$157.00US$80.00n/a23
Apr ’27US$74.45
US$100.64
+35.17%
15.87%US$157.00US$80.00n/a22
Mar ’27US$66.48
US$100.05
+50.49%
16.47%US$157.00US$80.00n/a21
Feb ’27US$77.27
US$93.00
+20.36%
18.12%US$157.00US$65.00n/a21
Jan ’27US$76.49
US$86.74
+13.40%
12.79%US$110.00US$65.00n/a19
Dec ’26US$71.78
US$84.94
+18.34%
14.17%US$110.00US$65.00n/a18
Nov ’26US$62.64
US$81.68
+30.40%
16.65%US$110.00US$63.00n/a19
Oct ’26US$53.48
US$66.32
+24.00%
16.65%US$95.00US$41.00n/a19
Sep ’26US$51.76
US$63.10
+21.90%
18.64%US$95.00US$41.00US$76.5721
Aug ’26US$47.37
US$61.59
+30.02%
18.84%US$95.00US$41.00US$80.0922
Jul ’26US$42.78
US$60.00
+40.25%
20.36%US$95.00US$41.00US$74.5219
Jun ’26US$34.25
US$58.78
+71.61%
20.86%US$95.00US$37.00US$65.3618
May ’26US$38.40
US$57.72
+50.32%
21.74%US$95.00US$37.00US$68.5618
Apr ’26US$33.02
US$53.82
+63.00%
24.18%US$95.00US$36.00US$74.4517
Mar ’26US$34.90
US$52.63
+50.79%
25.75%US$95.00US$36.00US$66.4816
Feb ’26US$34.21
US$49.49
+44.68%
17.82%US$70.00US$36.40US$77.2715
Jan ’26US$27.44
US$48.89
+78.18%
16.94%US$70.00US$36.40US$76.4915
Dec ’25US$27.09
US$48.53
+79.13%
16.63%US$70.00US$36.40US$71.7816
Nov ’25US$25.48
US$46.98
+84.38%
16.64%US$70.00US$36.70US$62.6416
Oct ’25US$24.80
US$47.31
+90.78%
16.98%US$70.00US$36.70US$53.4815
Sep ’25US$27.85
US$48.77
+75.11%
16.91%US$70.00US$37.00US$51.7613
US$109.1
Fair Value
38.9% undervalued intrinsic discount
21
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/21 03:59
End of Day Share Price 2026/09/18 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BridgeBio Pharma, Inc. is covered by 37 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Eliana MerleBarclays
"Eliana MerleBarclays
Jason ZemanskyBofA Global Research